2019

Afshar, Mehran, Patel, Hiten R. H., Jain, Ankit, Kumar, Abhishek, Patel, Prashant, James, Nicholas D. and Porfiri, Emilio (2019) Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC) : can this lead to the adverse effect of hypogonadism? Expert Review of Anticancer Therapy, 19 (6). pp. 529-532. doi:10.1080/14737140.2019.1609355

2018

Afshar, Mehran, Goodfellow, Henry, Jackson-Spence, Francesca, Evison, Felicity, Parkin, John, Bryan, Richard T., Parsons, Helen, James, Nicholas D. and Patel, Prashant (2018) Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance' : the case for super centralisation. BJU International, 121 (2). pp. 217-224. doi:10.1111/bju.13929

2017

(2017) UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics, 9 (1). 8. doi:10.1186/s13148-016-0303-5

2016

Andronis, L. (Lazaros) , Billingham, Lucinda J., Bryan, Stirling, James, Nicholas D. and Barton, Pelham (2016) A practical application of value of information and prospective payback of research to prioritize evaluative research. Medical Decision Making, 36 (3). pp. 321-334. doi:10.1177/0272989X15594369

(2016) Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. JAMA Oncology, 2 (4). pp. 493-499. doi:10.1001/jamaoncol.2015.5570

(2016) Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer. JAMA Oncology, 2 (3). pp. 348-357. doi:10.1001/jamaoncol.2015.4350

Real, Francisco X., Ward, Douglas G., Baxter, Laura, Gordon, Naheema S., Ott, Sascha, Savage, Richard S., Beggs, Andrew D., James, Jonathan D., Lickiss, Jennifer, Green, Shaun, Wallis, Yvonne, Wei, Wenbin, James, Nicholas D., Zeegers, Maurice P., Cheng, K. K., Mathews, Glenn M., Patel, Prashant, Griffiths, Michael and Bryan, Richard T. (2016) Multiplex PCR and next generation sequencing for the non-invasive detection of bladder cancer. PLoS One, 11 (2). pp. 1-11. e0149756. doi:10.1371/journal.pone.0149756

Vale, Claire L., Burdett, Sarah, Rydzewska, Larysa H. M., Albiges, Laurence, Clarke, Noel W., Fisher, David, Fizazi, Karim, Gravis, Gwenaelle, James, Nicholas D., Mason, Malcolm D., Parmar, Mahesh K. B., Sweeney, Christopher J., Sydes, Matthew R., Tombal, Bertrand and Tierney, Jayne F. (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer : a systematic review and meta-analyses of aggregate data. The Lancet Oncology, 17 (2). pp. 243-256. doi:10.1016/S1470-2045(15)00489-1

2015

Bahl, Amit, Masson, Susan, Malik, Zafar, Birtle, Alison J., Sundar, Santhanam, Jones, Rob J., James, Nicholas D., Mason, Malcolm D., Kumar, Satish, Bottomley, David, Lydon, Anna, Chowdhury, Simon, Wylie, James and de Bono, Johann S. (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU International, 116 (6). pp. 880-887. doi:10.1111/bju.13069

Kitchen, Mark O., Bryan, Richard T., Haworth, Kim E., Emes, Richard D., Luscombe, Christopher, Gommersall, Lyndon, Cheng, Kar K., Zeegers, Maurice P., James, Nicholas D., Devall, Adam J., Fryer, Anthony A. and Farrell, William E. (2015) Methylation of HOXA9 and ISL1 predicts patient outcome in high-grade non-invasive bladder cancer. PLoS One, 10 (9). pp. 1-12. e0137003. doi:10.1371/journal.pone.0137003

Bryan, R. T., Evans, T., Dunn, Janet A., Iqbal, Gulnaz, Bathers, S., Collins, S. I., James, Nicholas D., Catto, J. W. F. and Wallace, D. M. A. (2015) A comparative analysis of the influence of gender, pathway delays, and risk factor exposures on the long-term outcomes of bladder cancer. European Urology Focus, 1 (1). pp. 82-89. doi:10.1016/j.euf.2015.01.001

Afshar, Mehran, Evison, Felicity, James, Nicholas D. and Patel, Prashant (2015) Shifting paradigms in the estimation of survival for castration-resistant prostate cancer : A tertiary academic center experience. Urologic Oncology: Seminars and Original Investigations, 33 (8). 338.e1-338.e7. doi:10.1016/j.urolonc.2015.05.003

(2015) Management of patients with advanced prostate cancer : recommendations of the St. Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology, 26 (8). pp. 1589-1604. doi:10.1093/annonc/mdv257

Fizazi, Karim, Abrahamsson, Per-Anders, Ahlgren, Goran, Bellmunt, Joaquim, Castellano, Daniel, Culine, Stephane, de Wit, Ronald, Gillessen, Silke, Gschwend, Juergen E., Hamdy, Freddie, James, Nicholas D., McDermott, Raymond, Miller, Kurt, Wiegel, Thomas, Wirth, Manfred and Tombal, Bertrand (2015) Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe : introducing the prostate cancer consortium in Europe. European Urology, 67 (5). pp. 904-912. doi:10.1016/j.eururo.2014.08.076

James, Nicholas D., Sydes, Matthew R., Clarke, Noel W., Mason, Malcolm D., Dearnaley, David P. and Spears, Melissa R. (2015) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE) : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet, 387 (10024). pp. 1163-1177. doi:10.1016/S0140-6736(15)01037-5

Bryan, Richard T., Regan, H. L., Pirrie, S. J., Devall, A. J., Cheng, Kar K. , Zeegers, Maurice P., James, Nicholas D., Knowles, M. A. and Ward, D. G. (2015) Protein shedding in urothelial bladder cancer : prognostic implications of soluble urinary EGFR and EpCAM. British Journal of Cancer, 112 (6). pp. 1052-1058. doi:10.1038/bjc.2015.21

Afshar, Mehran, Al-Alloosh , F., Pirrie, S., Rowan, C., James, Nicholas D. and Porfiri, E. (2015) Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer. Anticancer Research, 35 (2). pp. 1057-1063.

McDonald, F., Waters, R., Gulliford, S., Hall, E., James, Nicholas D. and Huddart, R. A. (2015) Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clinical Oncology, Volume 27 (Number 1). pp. 22-29. doi:10.1016/j.clon.2014.09.016

2014

Afshar, Mehran, Pascoe, Jennifer, Whitmarsh, Sue, James, Nicholas D. and Porfiri, Emilio (2014) Temsirolimus for patients with metastatic renal cell carcinoma : outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center. Drug Design, Development and Therapy, Volume 2015 (Number 9). pp. 13-19. doi:10.2147/DDDT.S73686

Attard, Gerhardt, Sydes, Matthew R., Mason, Malcolm D., Clarke, Noel W., Aebersold, Daniel, de Bono, Johann S., Dearnaley, David P., Parker, Chris C., Ritchie, Alastair W. S., Russell, J. Martin, Thalmann, George, Cassoly, Estelle, Millman, Robin, Matheson, David, Schiavone, Francesca, Spears, Melissa R., Parmar, Mahesh K. B. and James, Nicholas D. (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. European Urology, 66 (5). pp. 799-802. 4. doi:10.1016/j.eururo.2014.05.038

(2014) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era” : data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). European Urology, 67 (6). pp. 1028-1038. doi:10.1016/j.eururo.2014.09.032

Loriot, Yohann, Fizazi, Karim, Jones, Robert J., Van den Brande, Jan, Molife, Rhoda L., Omlin, Aurelius, James, Nicholas D., Baskin-Bey, Edwina, Heeringa, Marten, Baron, Benoit, Holtkamp, Gertjan M., Ouatas, Taoufik and De Bono, Johann S. (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer : multi-centre phase I/II study. Investigational New Drugs, 32 (5). pp. 995-1004. doi:10.1007/s10637-014-0101-x

Slater, S. E., Patel, P., Viney, R., Foster, M., Porfiri, E., James, Nicholas D., Montgomery, B. and Bryan, Richard T. (2014) The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. The Annals of The Royal College of Surgeons of England, 96 (6). pp. 415-419. doi:10.1308/003588414X13946184901001

Fizazi, Karim, Massard, Christophe, Bono, Petri, Jones, Robert, Kataja, Vesa, James, Nicholas D., Garcia, Jorge M., Protheroe, Andrew, Tammela, Teuvo L. J., Elliott, Tony, Mattila, Leena, Aspegren, John, Vuorela, Annamari, Langmuir, Peter and Mustonen, Mika (2014) Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES) : an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. The Lancet Oncology, 15 (9). pp. 975-985. doi:10.1016/S1470-2045(14)70240-2

James, Nicholas D., Spears, Melissa R., Clarke, Noel W., Sydes, Matthew R., Parker, Christopher C., Dearnaley, David P., Russell, J. Martin, Ritchie, Alastair W. S., Thalmann, George, de Bono, Johann S., Attard, G., Amos, C., Parmar, Mahesh K. B. and Mason, Malcolm D. (2014) Impact of node status and radiotherapy on failure-free survival in patients with newly-diagnosed non-metastatic prostate cancer : data from > 690 patients in the control arm of the STAMPEDE Trial. Annals of Oncology, Volume 25 (Supplement 4). iv255-iv279. doi:10.1093/annonc/mdu336

Liu, Xiaoxuan, Dowell, Alexander C, Patel, Prashant, Viney, Richard P, Foster, Michael C, Porfiri, Emilio, James, Nicholas D. and Bryan, Richard T (2014) Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette–Guérin. Future Oncology, 10 (8). pp. 1443-1456. doi:10.2217/fon.14.79

Ploussard, Guillaume, Daneshmand, Siamak, Efstathiou, Jason A., Herr, Harry W., James, Nicholas D., Rödel, Claus M., Shariat, Shahrokh F., Shipley, William U., Sternberg, Cora N., Thalmann, George N. and Kassouf, Wassim (2014) Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer : a systematic review. European Urology, 66 (1). pp. 120-137. doi:10.1016/j.eururo.2014.02.038

(2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases : results from a phase 3, double-blind, randomised trial. The Lancet Oncology, Volume 15 (Number 7). pp. 738-746. doi:10.1016/S1470-2045(14)70183-4

Bryan, Richard T., Cheng, K. K. , James, Nicholas D., Zeegers, Maurice P. and Wallace, D. M. A. (2014) Re : defining progression in nonmuscle invasive bladder cancer : it is time for a new, standard definition. The Journal of Urology, 191 (6). pp. 1930-1931. doi:10.1016/j.juro.2014.01.011

(2014) A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU International, 113 (5b). E137-E143. doi:10.1111/bju.12564

Bryan, Richard T., Shimwell, N. J., Wei, W., Devall, A. J., Pirrie, Anne, James, Nicholas D., Zeegers, Maurice P., Cheng, Kar K., Martin, A. and Ward, D. G. (2014) Urinary EpCAM in urothelial bladder cancer patients : characterisation and evaluation of biomarker potential. British Journal of Cancer, 110 (3). pp. 679-685. doi:10.1038/bjc.2013.744

Tombal, B., Alcaraz, Antonio, James, Nicholas D., Valdagni, R. and Irani, J. (2014) Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer? BJU International, 113 (2). pp. 189-199. doi:10.1111/bju.12469

2013

Huddart, Robert A., Hall, E., Hussain, S. A., Jenkins, P., Rawlings, C. J., Tremlett, J., Crundwell, M., Adab, F., Sheehan, D., Syndikus, Isabel, Hendron, C., Lewis, R., Waters, R. and James, Nicholas D. (2013) A randomized non-inferiority trial of reduced high dose volume versus standard volume radiotherapy for muscle-invasive bladder cancer : results of the BC2001 trial (CRUK/01/004). International Journal of Radiation : Oncology - Biology - Physics, 87 (2). pp. 261-269. doi:10.1016/j.ijrobp.2013.06.2044

James, Nicholas D. (2013) Best palliation in advanced cancer is often achieved by treating the cancer. BMJ, 347 (7915). p. 1. f4648. doi:10.1136/bmj.f4648

(2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. The New England Journal of Medicine, 369 (3). pp. 213-223. doi:10.1056/NEJMoa1213755

van Roekel, Eline H., Cheng, Kar K., James, Nicholas D., Wallace, D. Michael, Billingham, Lucinda J., Murray, Paul G., Bryan, Richard T. and Zeegers, Maurice P. (2013) Smoking is associated with lower age, higher grade, higher stage, and larger size of malignant bladder tumours at diagnosis. International Journal of Cancer, 133 (2). pp. 446-454. doi:10.1002/ijc.28017

Bryan, Richard T., Zeegers, Maurice P., van Roekel, Eline H., Bird, Deborah, Grant, Margaret R., Dunn, Janet A., Bathers, Sarah, Iqbal, Gulnaz, Khan, Humera S., Collins, Stuart I., Howman, Andrew, Deshmukh, Nayneeta S., James, Nicholas D., Cheng, Kar Keung and Wallace, D. Michael A. (2013) A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU International, Volume 112 (Number 2). pp. 169-175. doi:10.1111/bju.12032

Morgan, Richard, Bryan, Richard T., Javed, Saqib, Launchberry, Francesca, Zeegers, Maurice, Cheng, Kar K. , James, Nicholas D., Wallace, Michael A., Hurst, Carolyn D., Ward, Douglas G., Knowles, Margaret A. and Pandha, Hardev (2013) Expression of engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. European Journal of Cancer, 49 (9). pp. 2214-2222. doi:10.1016/j.ejca.2013.01.019

Parker, Christopher C., Sydes, Matthew R., Mason, Malcolm D., Clarke, Noel W., Aebersold, Daniel, De Bono, Johann S., Dearnaley, David P., Ritchie, A. W. S., Russell, J. Martin, Thalmann, George, Parmar, Mahesh K. B. and James, Nicholas D. (2013) Prostate radiotherapy for men with metastatic disease : a new comparison in the systemic therapy in advancing or metastatic prostate cancer : evaluation of drug efficacy (STAMPEDE) trial. BJU International, 111 (5). pp. 697-699. doi:10.1111/bju.12087

(2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma : a retrospective analysis of pooled, prospective phase 2 trials. European Urology, 63 (4). pp. 717-723. doi:10.1016/j.eururo.2012.11.042

2012

James, Nicholas D., Sydes, Matthew R., Mason, Malcolm D., Clarke, Noel W., Anderson, John, Dearnaley, David P., Dwyer, John, Jovic, Gordana, Ritchie, Alastair W. S., Russell, J. Martin, Sanders, Karen, Thalmann, George N., Bertelli, Gianfilippo, Birtle, Alison J., O'Sullivan, Joe M., Protheroe, Andrew, Sheehan, Denise, Srihari, Narayanan and Parmar, Mahesh K. B. (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer : first results from the STAMPEDE multiarm, multistage, randomised controlled trial. The Lancet Oncology, 13 (5). pp. 549-558. doi:10.1016/S1470-2045(12)70088-8

Sydes, Matthew R., James, Nicholas D., Mason, Malcolm D., Clarke, Noel W., Amos, Claire, Anderson, John, de Bono, Johann S., Dearnaley, David P, Dwyer, John, Jovic, Gordana, Ritchie, Alastair W. S., Russell, Martin, Sanders, Karen, Thalmann, George and Parmar, Mahesh K. B. (2012) Flexible trial design in practice – dropping and adding arms in STAMPEDE : a multi-arm multi-stage randomised controlled trial. Trials, 12 (Supplement 1). A3. doi:10.1186/1745-6215-12-S1-A3

James, Nicholas D., Hussain, Syed A., Hall, Emma, Jenkins, Peter, Tremlett, Jean, Rawlings, Christine, Crundwell, Malcolm, Sizer, Bruce, Sreenivasan, Thiagarajan, Hendron, Carey, Lewis, Rebecca, Waters, Rachel and Huddart, Robert A. (2012) Radiotherapy with or without Chemotherapy in muscle-invasive bladder cancer. New England Journal Of Medicine , 366 (16). pp. 1477-1488. doi:10.1056/NEJMoa1106106

Hussain, S. A., Palmer, D. H., Lloyd, B., Collins, S. I., Barton, D., Ansari, J. and James, Nicholas D. (2012) A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncology Letters, 3 (4). pp. 855-859. doi:10.3892/ol.2012.563

2011

James, Nicholas D. (2011) Cancer : a very short introduction. Very Short Introductions . Oxford ; New York: Oxford University Press. ISBN 9780199560233

2010

Brown, Janet E., Sherriff, Jennifer M. and James, Nicholas D. (2010) Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy : an increasing, but under-recognized problem. BJU International, 105 (8). pp. 1042-1043. doi:10.1111/j.1464-410X.2010.09251.x

Gore, Martin E., Griffin, Clare L., Hancock, Barry, Patel, Poulam M., Pyle, Lynda, Aitchison, Michael, James, Nicholas D., Oliver, Roderick T. D., Mardiak, Jozef, Hussain, Tahera, Sylvester, Richard, Parmar, Mahesh K. B., Royston, Patrick and Mulders, Peter F. A. (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012) : an open-label randomised trial. The Lancet, 375 (9715). pp. 641-648. doi:10.1016/S0140-6736(09)61921-8

Sherriff, J. M., Brown, J. E. and James, Nicholas D. (2010) An under-recognised risk. BMJ, 340 (jan13 3). c143-c143. doi:10.1136/bmj.c143

Bryan, Richard T., Zeegers, Maurice P., James, Nicholas D., Wallace, D. Michael A. and Cheng, Kar Keung (2010) Biomarkers in bladder cancer. BJU International, 105 (5). pp. 608-613. doi:10.1111/j.1464-410X.2009.08880.x

James, Nicholas D., Caty, Armelle, Payne, Heather, Borre, Michael, Zonnenberg, Bernard A., Beuzeboc, Philippe, McIntosh, Stuart, Morris, Thomas, Phung, De and Dawson, Nancy A. (2010) Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU International, 106 (7). pp. 966-973. doi:10.1111/j.1464-410X.2010.09638.x

Dawson, Nancy, Payne, Heather, Battersby, Clare, Taboada, Maria and James, Nicholas D. (2010) Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). Journal of Cancer Research and Clinical Oncology, 137 (1). pp. 99-113. doi:10.1007/s00432-010-0864-1

Zeegers, Maurice P., Bryan, Richard T., Langford, Carolyn, Billingham, Lucinda, Murray, Paul, Deshmukh, Neeta S., Hussain, Syed, James, Nicholas D., Wallace, D. Michael A. and Cheng, K.K. (2010) The West Midlands bladder cancer prognosis programme : rationale and design. BJU International, 105 (6). pp. 784-788. doi:10.1111/j.1464-410X.2009.08849.x

Rossi, J-F., Négrier, S., James, Nicholas D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P. and Berns, B. (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. British Journal of Cancer, 103 (8). pp. 1154-1162. doi:10.1038/sj.bjc.6605872

2009

Patel, Prashant, Young, J Graham, Mautner, Vivien, Ashdown, Daniel, Bonney, Sarah, Pineda, Robert G., Collins, Stuart I., Searle, Peter F., Hull, Diana, Peers, Elizabeth, Chester, John, Wallace, D. Michael, Doherty, Alan, Leung, Hing, Young, Lawrence S. and James, Nicholas D. (2009) A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Molecular Therapy, Vol.17 (No.7). pp. 1292-1299. doi:10.1038/mt.2009.80

Onion, David, Patel, Prashant, Pineda, Robert G., James, Nicholas D. and Mautner, Vivien (2009) Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Human Gene Therapy, 20 (11). pp. 1249-1258. doi:10.1089/hum.2009.078

James, Nicholas D., Pascoe, J., Zachariah, A., Ray, D., Oldroyd, A., Parry, H., Benghiat, H., Karina, M., Collins, S. and Porfiri, E. (2009) Effect of the UK postcode lottery on survival of patients with metastatic renal cancer : an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors. Clinical Oncology, 21 (8). pp. 610-616. doi:10.1016/j.clon.2009.06.007

Sydes, Matthew R., Parmar, Mahesh K. B., James, Nicholas D., Clarke, Noel W., Dearnaley, David P., Mason, Malcolm D., Morgan, Rachel C., Sanders, Karen and Royston, Patrick (2009) Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer : the MRC STAMPEDE trial. Trials, 10 (1). 39. doi:10.1186/1745-6215-10-39

Sternberg, C. N., Petrylak, D. P., Sartor, O., Witjes, J. A., Demkow, T., Ferrero, J.-M., Eymard, J.-C., Falcon, S., Calabro, F., James, Nicholas D., Bodrogi, I., Harper, P., Wirth, M., Berry, W., Petrone, M. E., McKearn, T. J., Noursalehi, M., George, M. and Rozencweig, M. (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy : the SPARC trial. Journal of Clinical Oncology, 27 (32). pp. 5431-5438. doi:10.1200/JCO.2008.20.1228

Ansari, Jawaher, Fatima, Arfeen, Chaudhri, Shalini, Bhatt, Rupesh I., Wallace, Michael and James, Nicholas D. (2009) Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie , 32 (1-2). pp. 44-46. doi:10.1159/000183736

James, Nicholas D., Sydes, Matthew R., Clarke, Noel W., Mason, Malcolm D., Dearnaley, David P., Anderson, John, Popert, Richard J., Sanders, Karen, Morgan, Rachel C., Stansfeld, Jim, Dwyer, John, Masters, John and Parmar, Mahesh K. B. (2009) Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU International, 103 (4). pp. 464-469. doi:10.1111/j.1464-410X.2008.08034.x

(2009) A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. Applied Radiation and Isotopes, 67 (7-8). S31-S33. doi:10.1016/j.apradiso.2009.03.016

Patel, Prashant, Young, J Graham, Mautner, Vivien, Ashdown, Daniel, Bonney, Sarah, Pineda, Robert G., Collins, Stuart I., Searle, Peter F, Hull, Diana, Peers, Elizabeth, Chester, John, Wallace, D Michael, Doherty, Alan, Leung, Hing, Young, Lawrence S. and James, Nicholas D. (2009) A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Molecular Therapy, 17 (7). pp. 1292-1299. doi:10.1038/mt.2009.80

2008

Young, J. G., Green, N. K., Mautner, V., Searle, P. F., Young, Lawrence S. and James, Nicholas D. (2008) Combining gene and immunotherapy for prostate cancer. Prostate Cancer and Prostatic Diseases, Vol.11 (No.2). pp. 187-193. doi:10.1038/sj.pcan.4501008

(2008) Optimizing treatment for men with advanced prostate cancer : expert recommendations and the multidisciplinary approach. Critical Reviews in Oncology/Hematology, 68 (1). S9-S22. doi:10.1016/j.critrevonc.2008.07.019

James, Nicholas D., Sydes, Matthew R., Clarke, Noel W., Mason, Malcolm D., Dearnaley, David P., Anderson, J., Popert, Richard J., Sanders, K., Morgan, Rachel C., Stansfeld, J., Dwyer, John, Masters, J. and Parmar, Mahesh K. B. (2008) STAMPEDE : systemic therapy for advancing or metastatic prostate cancer - a multi-arm multi-stage randomised controlled trial. Clinical Oncology, 20 (8). pp. 577-581. doi:10.1016/j.clon.2008.07.002

Parmar, Mahesh K. B., Barthel, F. M.- S., Sydes, Matthew R., Langley, R., Kaplan, R., Eisenhauer, E., Brady, M., James, Nicholas D., Bookman, M. A., Swart, A.-M., Qian, W. and Royston, P. (2008) Speeding up the evaluation of new agents in cancer. JNCI Journal of the National Cancer Institute, 100 (17). pp. 1204-1214. doi:10.1093/jnci/djn267

Sikora, K. and James, Nicholas D. (2008) Top-up payments in cancer care. Clinical Oncology, 21 (1). doi:10.1016/j.clon.2008.11.002

James, Nicholas D., Williams, M. V., Summers, E. T., Jones, K. and Cottier, B. (2008) The management of interruptions to radiotherapy in head and neck cancer : an audit of the effectiveness of national guidelines. Clinical Oncology, 20 (8). pp. 599-605. doi:10.1016/j.clon.2008.05.003